EnGenBio Passes 3rd Pilot Project for 'DTC Genetic Testing Service Certification' Led by Ministry of Health and Welfare

Providing the Nation's Largest 70 Types of Genetic Testing Services Soon

[Asia Economy Reporter Lee Gwan-joo] Precision diagnostic platform specialist NGENBIO announced on the 25th that it has passed the third pilot project certification for DTC (Direct-to-Consumer) genetic testing services, led by the Ministry of Health and Welfare.

Following the second pilot project (covering 45 types) in March last year, NGENBIO plans to offer a total of 70 genetic testing services, the largest number in Korea, by passing certification for an additional 25 types in this third pilot project. The company plans to classify some of the 70 certified items into detailed categories to provide consumers with more diverse and accurate testing services.

The items added in this third pilot project include nine nutrients such as lutein and zeaxanthin, vitamin A, and vitamin E, as well as health management-related items that are useful and of high consumer interest, such as post-exercise recovery ability, alcohol dependence, nicotine dependence, and insomnia. Additionally, beauty-related items such as gray hair, acne occurrence, and male pattern baldness were also included.

NGENBIO’s DTC genetic testing service, ‘Genorhythm,’ has shown remarkable growth since its launch last year, with over 100,000 tests conducted. The company expects that certification in this third pilot project will contribute to providing higher quality services and expanding its customer base. They plan to upgrade differentiated content based on individual genetic test results and develop mobile services for consumer convenience to offer optimal personalized health management solutions.

Choi Dae-chul, CEO of NGENBIO, stated, “Passing the third pilot project allows us to provide consumers with more sophisticated genetic testing services,” adding, “Based on this, we will continuously accumulate detailed genetic testing data to build a platform integrating disease genetic data and microbiome data.” He further commented, “In the future, we will be able to provide personalized healthcare services that allow each customer to check their condition and experience effective results.”

This content was produced with the assistance of AI translation services.